Skip to content
★ Sign in to follow
FC

Finemedix Co., Ltd. Stock: price and insider trades · South Korea

파인메딕스

KR·Mcap ₩33.2BHealth Care

No insider purchase over the last 90 days. The latest, by 이문수, was filed 26 Jun 2026.

Finemedix Co., Ltd.: what insiders have been doing

Every trade that managers of Finemedix Co., Ltd. disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. Between 9 November 2025 and 9 November 2026, 2 insiders published 3 filings.

On the market, 1 insider bought (1 purchase) while 1 insider sold (2 sales). The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 major shareholder among the declarants.

The last insider purchase was made public on 26 June 2026, 136 days ago. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

For context, the typical company on the same exchange (median of 2,630 companies) published 7 filings over the same period, against 3 filings here. Our records for Finemedix Co., Ltd. go back to 2024, with 6 purchases and 2 sales on the open market in total.

In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.

Insider Decl.
8
Thresholds
n/a
Buy Volume
n/a
6 ops. · all time
Sell Volume
n/a
2 ops. · all time

Who traded when

BuySale
엔브이씨파트너스1 buy2 sales
전성우2 buys
김성철1 buy
이문수1 buy
황중보1 buy
Fundamental score
Ranked 22,924 of 26,913 companies
26.4
score / 100
Value
18
Quality
35
FCF yld-11%
Earn yld-5.7%
EV/EBITDA·
ROE-3.1%
Gross mgn48%
Net mgn-20%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩6,110
Analyst consensus
·
Income statement
Revenue₩9.5B
Gross profit₩4.6B48% margin
EBITDA-₩1.5B-16% margin
Net income-₩1.9B-5.2% margin
Balance sheet & cash
Market cap₩33.2B
Total debt₩3.9B
Free Cash Flow-₩3.5B
Debt / Equity12%
Profitability & ownership
ROE-3.1%
ROA-3.0%
% insiders37.1%
% institutions0.0%
Last declaration on 26 June 2026
Declarations8 total
  • ▲
    대량보유자Executives(filed)
    0DART
    317,562 sharesKRXDART:20260626000543
    Canonical exit: 24 Sept 2026 (T+90)
  • ▼
    Related company / holdingExecutives(filed)
    0DART
    328,333 sharesKRXDART:20260626000456
  • ▼
    Related company / holdingExecutives
    0DART
    426,780 sharesKRXDART:20260107000227
  • ▲
    Related company / holdingExecutives
    0DART
    818,200 sharesKRXDART:20250106000003
    Canonical exit: 26 Mar 2025 (T+90)
  • ▲
    Executives
    0DART
    2,031,300 sharesKRXDART:20241231000388
    Canonical exit: 26 Mar 2025 (T+90)
  • ▲
    이사Executives
    0DART
    ShareKRXDART:20241231000174
    Canonical exit: 26 Mar 2025 (T+90)
  • ▲
    대표이사Executives
    0DART
    ShareKRXDART:20241231000170
    Canonical exit: 26 Mar 2025 (T+90)
  • ▲
    부사장Executives
    0DART
    ShareKRXDART:20241231000171
    Canonical exit: 26 Mar 2025 (T+90)

8 of 8 declarations

About Finemedix Co., Ltd.

파인메딕스 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative medical solutions.